Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Abstract: A disposable cartridge for a drug delivery device includes a flexible bag to accommodate a liquid medicament and having an opening adjacent to a sidewall, a socket having a fluid channel in fluid communication with a cartridge fluid coupling, and a housing covering at least a portion of the flexible bag and having a receptacle to receive the socket with the flexible bag. The socket extends into the opening of the flexible bag. The flexible bag's sidewall is fixed between the socket and the receptacle.

Abstract: Described is a medicament delivery device comprising a case adapted to hold a container with a medicament and having a needle, a needle sleeve telescopically coupled to the case and having a first extended position relative to the case in which the needle is covered, a retracted position relative to the case in which the needle is exposed, and a second extended position relative to the case in which the needle is covered, a first indicia disposed on the needle sleeve which is visible in the first extended position and the second extended position, and a second indicia disposed on the needle sleeve and not visible in the first extended position and visible the second extended position.

Abstract: The present disclosure relates to a cap for an injection device. The injection device comprises a body for holding a syringe having a needle extending from an end thereof. The cap is removably attachable to the body. The cap comprises an actuator and a needle shield to cover said needle. The cap further comprises a coupling between the actuator and the needle shield. The coupling is configured such that when the cap is attached to the body of the injection device axial movement of the actuator away from the body causes rotation of the needle shield relative to the body.

Abstract: A coding system for a drug reservoir, where the drug reservoir is intended for use with a reservoir holder of a drug delivery device. The coding system includes a collar fitted around the drug reservoir. The collar includes a coding feature that is configured to pass through a corresponding coding feature provided by the reservoir holder of the drug delivery device.

Abstract: Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.

Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.

Abstract: The present disclosure relates to a packaging for a medicament container, wherein the medicament container comprises at least one distal container abutment section and at least one proximal container abutment section, the packaging comprising: a bottom and a sidewall structure connected to the bottom, the bottom and the sidewall structure confining a storage space configured to accommodate at least one medicament container, at least one distal packaging abutment section, and at least one proximal packaging abutment section, wherein the at least one distal packaging abutment section is integrated into or arranged at one of the sidewall structure and the bottom and configured to abut with the at least one distal container abutment section, wherein the at least one proximal packaging abutment section is integrated into or arranged at the sidewall structure and configured to abut with the at least one proximal container abutment section.

Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.

Abstract: The present disclosure relates to novel nucleotide precursors and nucleotide analogs that can be incorporated into oligonucleotides, including double-stranded oligonucleotides such as siRNAs. Oligonucleotides containing these analogs have superior biological activity, for example, increased in vitro stability and improved in vivo potency especially duration of action. The improved oligonucleotides are useful for silencing (e.g., reducing or eradicating) the expression of a target gene. In particular embodiments, this invention encompasses specific nucleotide analogs to be included in double-stranded RNAs (dsRNAs), and especially in siRNAs, that can hybridize to messenger RNAs (mRNAs) of interest, so as to reduce or block the expression of target genes of interest. The present compounds have general formula (I), wherein each of Ra, Rb, Rc and Rd is independently, H or a (C1-C6) alkyl group and B is a heterocyclic nucleobase.

Abstract: The present invention concerns a cell line comprising an endogenous dihydroorotate dehydrogenase (DHODH) and glutamine synthetase (GS) genes which are partially or fully inactivated, and its use for producing recombinant proteins.

Abstract: Apparatus for recording information concerning the use of an injection device, the apparatus comprising: one or more sensors for providing information indicative of how the injection device is used; a processor configured to analyse said information detected by the one or more sensors to determine use information, said use information corresponding to how the injection device is used; and a memory for storing said use information in an image format such that said use information can be retrieved from the memory and displayed in an image.

Abstract: Described is a system comprising an input module receiving a first data set indicative of at least one patient condition for each of a plurality of patients obtained during a predetermined time period, a comparison module comparing each of the at least one patient condition to at least one filter criteria, a filter module selecting a patient to include in a second data set if the at least one patient condition of the patient satisfies the at least one filter criteria, a report module generating a report based on the second data set, wherein the report includes at least one patient identifier for each patient in the second data set and at least one descriptor of the at least one patient condition for each patient in the second data set, and a classification module storing at least one classification value for the at least one patient condition.

Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.

Abstract: The present disclosure relates to a measurement probe for measuring a mechanical load. The measurement probe includes: an elongated body comprising a tubular portion configured for insertion into a cartridge holder of an injection device, a sensor tab arranged on or integrated into the elongated body, wherein the sensor tab comprises an outside surface portion, an inside surface portion and an outer abutment section, wherein the outer abutment section is configured to abut with an inside of a sidewall of the cartridge holder and wherein the sensor tab is deformable in a radial direction, a sensor element mechanically connected to the at least one sensor tab and configured to measure a deformation of the at least one sensor tab.

Abstract: An electronic device comprising: a housing for attachment to an injection device; a first sensor assembly comprising a first coil and two magnets of opposite polarity, wherein the first coil is configured to provide a first voltage pulse as a first Wiegand wire of the injection device moves from a first position proximate to one of the magnets of the first sensor assembly to a second position proximate to the other magnet of the first sensor assembly; and one or more processors configured to enter an enabled state from a sleep state after receiving the first voltage pulse from the first coil.

Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.

Abstract: A drive train for a wind-up injection device is described. The drive train includes a torsional energy storage adapted to be loaded or unloaded by a rotatable element, a rotatable user handle, a rotationally driveable expelling mechanism adapted to expel the liquid drug, and a clutch element coupled with the torsional energy storage via the rotatable element and including a ratchet for maintaining the rotatable element at one of a number of discrete angular positions against the torque of the torsional energy storage. The clutch element is adapted to transmit the torque from the user handle to the torsional energy storage, or alternatively from the torsional energy storage to the expelling mechanism. The ratchet is switchable from one position to an adjacent position by a torque transmitted from the user handle to the torsional energy storage. The drive train is adapted to dampen torque peaks visco-elastically and/or visco-frictionally.